Source: Aurora Spine Corporation.
  • Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors
  • 11,220,930 units will be issued at a price of $0.58 per common share and associated common warrant
  • It expects the closing date to occur on or about September 17, 2021
  • Aurora Spine Corporation brings new solutions to the spinal implant market through minimally invasive regenerative spinal implant technologies
  • Aurora Spine Corporation (ASG) closed down by 10.94 per cent trading at $0.57 per share

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.

It will issue up to 11,220,930 units priced at $0.58 per common share and associated common warrant.

Each warrant entitles the holder to purchase one common share for $0.75 for up to three years after the closing of the offering.

Aurora expects the closing date to occur on or about September 17, 2021.

Aurora will offer shares and warrants in the United States on a private placement basis pursuant to exemptions from the registration requirements of the United States Securities Act of 1933.

No securities will be sold or offered for sale in Canada.

Aurora Spine Corporation brings new solutions to the spinal implant market through minimally invasive regenerative spinal implant technologies.

Aurora Spine Corporation (ASG) closed down by 10.94 per cent trading at $0.57.

More From The Market Online

MindBio debuts AI speech tool to spot substance abuse

MindBio Therapeutics (CSE:MBIO) develops the world's first AI prediction tool for drug and alcohol intoxication using voice analysis.

An immunotherapy value play advancing the fight against bladder cancer

An in-depth look at BioVaxys Technology (CSE:BIOV), a micro-cap stock combining a promising drug pipeline with irrational investor pessimism.
The Market Online Video

Developing a neurosciences platform with potential applications across several indications

In this Capital Compass episode, Marvel Biosciences outlines progress on MB-204, its neuroscience platform targeting autism, Rett syndrome, Fragile X, and Alzheimer’s disease ahead…